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Stable liquid formulationDespite solid evidence of the success of rotavirus vaccines in saving children from fatal gastroenteritis,
more than 82 million infants worldwide still lack access to a rotavirus vaccine. The main barriers to global
rotavirus vaccine coverage include cost, manufacturing capacity and suboptimal efficacy in low- and
lower-middle income countries. One vaccine candidate with the potential to address the latter is based
on the novel, naturally attenuated RV3 strain of rotavirus, RV3-BB vaccine administered in a birth dose
strategy had a vaccine efficacy against severe rotavirus gastroenteritis of 94% at 12 months of age in
infants in Indonesia. To further develop this vaccine candidate, a well-documented and low-cost manu-
facturing process is required. A target fully loaded cost of goods (COGs) of $3.50 per course of three
doses was set based on predicted market requirements. COGs modelling was leveraged to develop a pro-
cess using Vero cells in cell factories reaching high titers, reducing or replacing expensive reagents and
shortening process time to maximise output. Stable candidate liquid formulations were developed allow-
ing two-year storage at 2–8 C. In addition, the formulation potentially renders needless the pretreatment
of vaccinees with antacid to ensure adequate gastric acid neutralization for routine oral vaccination. As a
result, the formulation allows small volume dosing and reduction of supply chain costs. A dose ranging
study is currently underway in Malawi that will inform the final clinical dose required. At a clinical dose
of 6.3 log10 FFU, the COGs target of $3.50 per three dose course was met. At a clinical dose of 6.5 log10
FFU, the final manufacturing process resulted in a COGs that is substantially lower than the current aver-
age market price, 2.44 USD per dose. The manufacturing and formulation processes were transferred to
BioFarma in Indonesia to enable future RV3-BB vaccine production.
 2021 Batavia Biosciences BV. Published by Elsevier Ltd. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Rotavirus is a leading cause of mortality for neonates and
children, in the absence of an effective vaccine nearly all children
worldwide acquire a rotavirus infection by age five [1]. Symptoms
include fever, vomiting and watery diarrhea which may lead to
fatal dehydration [1]. Two rotavirus vaccines, RotaTeq (Merck &
Co, Kenilworth, NJ, USA) and Rotarix (GlaxoSmithKline Biologi-
cals, London, UK) were prequalified by the World Health Organiza-
tion (WHO) in 2008 and 2009, respectively [2]. These vaccines have
significantly reduced child mortality from gastroenteritis [1,3,4].
Despite availability of these vaccines, rotavirus remains one of
the main causes of mortality among children under five years of
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settings in low-to-middle income countries with limited health
care infrastructure and access [4–6]. Despite evidence of the
success of rotavirus vaccines, more than 88 million infants still lack
access to a rotavirus vaccine [6,7]. Barriers to global implementa-
tion of the vaccine include cost, limited manufacturing capacity,
suboptimal efficacy in low-income countries and safety concerns
[5]. The 2018 WHO prequalification of ROTAVAC (Bharat Biotech,
Hyderabad, India) and ROTASIIL (Serum Institute of India, Pune,
India), and the availability of locally produced and licensed vacci-
nes (Rotavin, Polyvac, Vietnam and Lamb rotavirus, Lanzhou Insti-
tute of Biological Products, China), should partially alleviate cost
and supply barriers, however, there remains the challenge of
sub-optimal efficacy of the current vaccines in low-income coun-
tries [4,8]. Thus far, all licensed oral rotavirus vaccines had a high
efficacy (>80%) in high- and middle income settings and lower effi-
cacy (40–67%) in low-income settings despite having high vaccina-
tion coverage [4,5]. Reasons for the lower efficacy remain unclear
and interventions to improve efficacy in developing settings (e.g.
withholding breastfeeding, adding buffers, micronutrient supple-
mentation) have failed to yield definitive or actionable results
[4,5]. In addition, availability of a range of rotavirus vaccine options
with heterogeneous characteristics including different presenta-
tions, dosing schedules, and prices can also present decision mak-
ers with more complex choices in selecting a vaccine product [9].
For example, dosages are indicated in different units such as cell
culture infectious dose 50% (CCID50) vs FFU vs international units
(IU), used in different schemes (2 dose vs 3 dose), and single versus
multiple strains per dose (Table 1). In current vaccination sched-
ules, a three dose rotavirus vaccine (RotaTeq, ROTAVAC and
ROTASIIL) is administered at 6–8, 10–14 and 14–18 weeks of
age, or in a two dose vaccine schedule (Rotarix) at 6–8 and 10–
14 weeks (ranges as recommended by WHO and advised by the
manufacturers) [10–12]. Therefore, neonates remain at risk of
being exposed to rotavirus in the period from birth until 6–8 weeks
of age before the first vaccine dose is given [6], indicating the need
for a vaccine that can be administered directly at birth [13]. This is
of particular importance in low- and lower-middle income coun-
tries (LICs and LMICs), where access to vaccines is poor, there is
earlier onset of rotavirus disease, and the burden of disease is sig-
nificant [6,13]. The currently approved vaccines, listed above, have
not been licensed with a neonatal dose.
To address current barriers and challenges, several new
rotavirus vaccines are in different stages of pre-clinical and clinical
development [5,8,14], and include live-attenuated, oral rotavirus,
and non-replicating (e.g. virus-like-particles, recombinant subunit,
or inactivated rotavirus), parenterally delivered rotavirus vaccines.
One of the new promising live-attenuated oral rotavirus vaccines
concepts is based on the RV3 rotavirus strain (G3P[6]) isolated
from a newborn in Melbourne (Australia), and is currently under
development at Murdoch Children’s Research Institute (MCRI),
Australia.
The RV3-BB human neonatal rotavirus vaccine was developed
to provide protection from severe rotavirus disease from birth
[15,16]. The attenuated human rotavirus strain (G3P[6]) has beenTable 1
Summary of WHO prequalified rotavirus vaccines.
Rotavirus vaccine Virus titer per aggregate dose Unit Regimen
RotaTeq <8.1* log10 IU 3-dose
Rotarix 6.0 log10 CCID50 2-dose
ROTAVAC 5.0 log10 FFU 3-dose
ROTASIIL 6.3** log10 FFU 3-dose
* A minimum of 2.0–2.8  106 infectious units (IU) per individual reassortant dose, d
** Recalculated for 5 strains from 105.6 FFU/serotype.
2049shown to be associated with asymptomatic infection in newborns
and provide protection against severe rotavirus infection in the
first 3 years of life [15,16]. Due to an earlier peak age of disease
in high-mortality settings, the neonatal schedule may provide an
earlier protection when compared with the infant schedule [17].
In a recent randomized placebo-controlled efficacy study con-
ducted in Central Java and Yogyakarta, Indonesia, three doses of
RV3-BB in Indonesian infants resulted in 75% efficacy against sev-
ere rotavirus gastroenteritis in the first 18 months of life when
administered in a neonatal schedule (at ages 0–5 days, 8 weeks,
and 14 weeks) compared with 51% when administered in an infant
schedule (ages 8, 14, and 18 weeks), suggesting that the birth dose
might enhance protection [3,6]. The aim of the Central Java and
Yogyakarta study was to investigate vaccine efficacy against severe
rotavirus disease in the first 18 months of life [6]. A secondary out-
come was to assess for impact of coadministration with OPV vs IPV
on immunogenicity of RV3-BB rotavirus vaccine and OPV [3]. The
co-administration of OPV with RV3-BB rotavirus vaccine in a birth
dose strategy did not reduce the immunogenicity of either vaccine.
These findings support the use of a neonatal RV3-BB vaccine in the
routine vaccination schedule [3]. Moreover, use of RV3-BB pro-
duced vaccine take irrespective of histo-blood group antigen
(HBGA) status, and showed potential to provide an improved pro-
tection in settings where P[6] rotavirus is endemic [18]. Human
genetic diversity has an effect on rotavirus infections susceptibility
and vaccine take [19]. Innate resistance to viral infections can be
attributed to mutations in genes involved in the immune response,
or to the receptor/ligand. This resistance appears to be rotavirus
genotype-dependent and is mainly mediated by HBGAs, which
function as a receptor or attachment factors on gut epithelial
surfaces [19].
The RV3-BB vaccine is shown to be safe and immunogenic, and
is currently in clinical phase III development at BioFarma, Indone-
sia [8,14], with the intention to have a birth dose vaccination
schedule [3,6]. Another unique feature is that RV3-BB contains
the targets P[6] genotype that may offer an advantage in regions
(such as Africa and Asia) where P[6] strains are commonly associ-
ated with severe disease in children, as the vaccine appears to bind
to receptors irrespective of HBGA status [18,20]. Given these
promising characteristics, we set out to develop a scalable and
low-cost process, that allows for the robust large-scale production
of a liquid RV3-BB rotavirus vaccine. Three major goals were
established for the study: (i) the developed process should allow
scale-up to large-scale commercial production of the RV3-BB vac-
cine at a desired manufacturing COGs of a maximum of 3.50 USD
per complete vaccination course (expected to be 3 doses per
course), (ii) the trypsin used for drug substance manufacturing
should be of an animal-component-free, non-porcine, origin for
safety reasons and (iii) the developed liquid vaccine formulation
should be stable for two years at 2–8 C and does not require
pre-neutralization of gastric acid upon administration (i.e. vaccine
is stable during long-term storage and during passage through the
stomach). In regards to these vaccine formulation goals, it is
known that licensed rotavirus vaccines use buffering excipients
to minimize vaccine virus inactivation due to acidic conditions inNumber of strains per dose Administrationat weeks of age Refe-rence
Five 8, 14 and 18 [12]
One 8 and 14 [49]
One 8, 14 and 18 [50]
Five 8, 14 and 18 [42]
epending on the serotype, and not greater than 116  106 IU per aggregate dose.
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diluent results in the undesirable need for separate transport
and storage and oral administration steps. In addition, oral
administration of relatively large volumes (1.5 to 2.5 mL) of
reconstituted or ready-to-use vaccine to infants is less preferred
[21,22]. Immunization programs prefer oral vaccines in smaller
volumes (e.g. 0.5 to 1.0 mL) that are ready-to-use and do not
require reconstitution or administration of separate components,
such as a diluent or a buffer, to minimize errors in administration.
The formulation development of the RV3-BB vaccine candidate
that meets these vaccine dosage form objectives has been
described in detail elsewhere [23–25].
In summary, the following studies provide for a manufacturing
process that has the potential to meet the target COGs of  3.50
USD per complete vaccination course of 3 doses. In addition, the
liquid oral rotavirus vaccine (ORV) formulation, intended for
neonatal use, is stabilized at refrigerator temperature (2–8 C),
and could protect the virus from inactivation in the gastric acid
environment of the stomach. We believe further studies are war-
ranted as this RV3-BB vaccine candidate has the potential to
address the sub-optimal efficacy, supply, and price challenges
currently encountered in the fight against rotavirus.Fig. 1. A) Reproducible Vero cell growth (n = 21; error bars indicate 95%CI) in the
iCELLis fixed-bed bioreactor. B) Rotavirus production in the iCELLis fixed-bed
bioreactor is dependent on the trypsin source used to activate the virus (error bars
indicate standard deviation). C) Rotavirus production in Cell Factory systems. The
same trypsin sources as used in the iCELLis bioreactor (see figure B) show an
opposite effect when used in the Cell Factory system (error bars indicate standard
deviation; no significant difference was observed in the virus titers obtained
between using trypsin type 2 compared with type 3). Cell Factory systems were
selected as production system for RV3-BB. In the USP harvest, the obtained virus
titer was on average 7.3 ± 0.3 log10 FFU/mL (n = 12), based on using Trypsin type 3.2. Results
2.1. Production of RV3-BB virus
Two cell culture systems were evaluated for manufacture of the
rotavirus vaccine: an iCELLis bioreactor and stacked cell culture
flasks (Cell FactoryTM system). Both systems are extensively used
in the commercial vaccine and viral vector manufacturing industry
[26–29]. Based on the data shown in Fig. 1A it was concluded that
the Vero cells could be readily cultured to 3.3 ± 0.7  105 cells per
cm2 (n = 21) in an iCELLis system, providing a high cell density bio-
mass for the infection with the attenuated RV3-BB strain.
As little is known about the kinetics of rotavirus replication in
Vero cells, and trypsin is pivotal for virus activation to facilitate cell
entry, a number of studies were performed in Design of Experi-
ments (DOE) mode in the iCELLis bioreactor. Parameters assessed
included trypsin concentration at infection and in the maintenance
medium, bed compaction, cell density at infection, multiplicity of
infection, volume at infection, source of Vero cells, culture media
feeding and harvest methods. From the data obtained (not shown)
it was concluded that none of these parameters substantially
improved RV3-BB virus titer in the iCELLis bioreactor with optimal
results obtained in this system at 7.0 ± 0.2 log10 FFU/mL (n = 6),
when using porcine trypsin.
One striking outcome from the DOE studies was related to
use of trypsin in the two selected culture systems. As shown
in Fig. 1B, trypsin type-1 (derived from porcine origin and used
as reference) consistently provided the highest titer in the
iCELLis bioreactor whereas trypsin type-2 and type-3 (both of
animal-component-free origin) were superior in the Cell Factory
system (Fig. 1C). Although poorly understood, one hypothesis is
that the reduced accessibility of the cells in a fixed-bed
bioreactor compared to a static cell culture system, combined
with the chemical-physiological properties of the trypsin
materials tested, significantly contributed to the difference seen
in virus titer. Based on the results obtained, it was decided to
continue the upstream cell and virus culture process develop-
ment using the Cell Factory system. Typically, upon producing
virus on a routine basis for purification studies using trypsin
type-3, a virus titer of 7.3 ± 0.3 log10 FFU/mL (n = 12) was
achieved in this system. In addition, the DOE studies performed
in the Cell Factory system, enabled design of a production2050protocol that delivered the highest possible titer of RV3-BB virus
including a substantial shortening of the process time (from
overall 44 to 22 days) due to an adapted Vero cell preculture
schedule, an optimal cell density at infection (CDAI) of
2.1  105 cells/cm2, and a significant 10x reduction in the mul-
tiplicity of infection (MOI). All these findings were implemented
in the cost modeling studies described below.
Table 2
In-process residuals levels following UF/DF, with and without the use of Benzonase







Host Cell DNA 20 40,600
BSA <1 2
Host Cell Protein 5440 5557
Benzonase < LLOQ* < LLOQ*
* LLOQ = Lower Level of Quantification = 5 ng/mL.
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Ultracentrifugation is a commonly used, lab-scale method for
rotavirus purification. However, ultracentrifugation-based meth-
ods require expensive equipment, are challenging in scale-up,
and less suitable for GMP manufacturing. Therefore, a scalable
downstream process (DSP) was developed. Following virus harvest
and virus release from the Vero cells by freeze-thawing (for Cell
Factory harvests only), a DSP was developed consisting of (i) Ben-
zonase treatment, (ii) clarification, (iii) ultrafiltration/diafiltration
(UF/DF) and (iv) a final filtration step. Overall RV3-BB virus
recoveries obtained after each step are shown in Fig. 2. For
development of a clarification step to reduce Vero host cell debris,
a number of filter materials and pore sizes were screened resulting
in a virus recovery of 80% at small scale (1–3 L volume) and >70%
at larger scale (14 L volume). Prior to clarification, host-cell DNA
digestion was performed using Benzonase. After clarification,
oligonucleotides were removed by ultrafiltration. During the UF/
DF step, it was observed that an initial Benzonase treatment
was pivotal to reduce membrane fouling and improve virus recov-
ery. The addition of Benzonase resulted in a >1000-fold reduction
of the host-cell DNA residuals (from 40,600 ng/ml to 20 ng/ml;
Table 2). For live-attenuated vaccines such as rotavirus vaccines
that are delivered orally, residual host-cell DNA should be limited
to 100 lg/dose [30] [Ph. Eur. 10.0, 2417 (01/2012)], as orally
administered DNA is absorbed approximately 10,000-fold less effi-
ciently than parenterally administered DNA [31]. With the use of a
final filtration step (0.2 mm pore-size), the overall recovery was
reduced from >50% to 31% (Fig. 3). Although several different filter
membranes, surfactants and buffers were tested, none improved
the recovery of RV3-BB virus during this process step (data not
shown). Here, it can be argued that the final filtration step could
be omitted as a bioburden reduction step, in combination with
aseptic processing, can suffice. Although this was not further
modelled in these studies, omitting a final filtration step would
clearly have a substantial impact on overall RV-3 BB virus recovery.
In summary and as shown schematically in Fig. 3, a drug
substance (DS) manufacturing process was developed, delivering
a yield of 7.3 ± 0.3 log10 FFU/mL in the upstream process (USP) uti-
lizing Cell Factory systems and an overall RV3-BB virus recovery of
30% in the DSP post final filtration. An animal-component-free
trypsin (type-3) was successfully introduced in the production
process.Fig. 2. High infectious rotavirus recovery percentages per unit operation were
obtained starting with the Cell Factory harvest, up to and including the UF/DF-stage.
For aseptic processing, the cumulative virus recovery including the UF/DF-stage
was >50%. However, the overall virus recovery was reduced to 31% when a filtration
unit operation needs to be included.
20512.3. Analytical methods for RV-3 BB vaccine development
Assays described were developed according ICH Q2 analytical
validation guidelines [32] and WHO guidelines [30]. To support
release testing for bulk harvest, an identity polymerase chain reac-
tion (PCR) was developed for virus identity testing and a fluores-
cent focus assay (FFA) was developed for the quantification of
virus concentration. To support drug substance release testing, in
addition to FFA, an assay was developed to quantify residual
host-cell DNA. Additional tests were developed to support process
development and validation and included residual bovine serum
albumin (BSA), Benzonase and host cell protein. An assay was
not needed to assess the level of residual trypsin; a risk assessment
determined that trypsin residuals were under the detection limit.
In addition to the assays developed to support product release, a
high-performance size-exclusion chromatography (HP-SEC)
method for virus particle quantification was developed to support
process development, process optimization and product character-
ization. The need for such an in-process assay became apparent
while executing the DOE studies to optimize production of the
RV-3 BB virus. Results of the novel HP-SEC method regarding assay
specificity and quantification are shown in Fig. 4A and B, respec-
tively. For total rotavirus particles analysis, the HP-SEC method
was shown to be specific (baseline separated peak without matrix
interference) and linearity was shown (r2 > 0.99) within a defined
concentration range. Subsequently, the HP-SEC method was imple-
mented in DSP for recovery calculations. During USP, the HP-SEC
method was used for particle size profiling and in-process yield
monitoring. In USP samples, virus quantification by HP-SEC was
used following Benzonase treatment of the sample. Based on
the data obtained, it was concluded that this additional assay
methodology (HP-SEC) for virus particle quantification delivered
a semi-quantitative, high-throughput assay, without the relatively
high variation, as is the case with biological assays such as the FFA.
However, this method cannot differentiate between infectious and
non-infectious viral particles. It is intended as an in-process
method to quickly assess the virus yields. For product dosing the
infectious titer needs to be determined separately.2.4. Formulation of RV-3 BB virus
As described in detail elsewhere [23–25], formulation
development studies with RV3-BB identified a series of promising
candidate liquid formulations. To investigate potentially stabilizing
additives, ~50 different excipients from various excipient cate-
gories (e.g., sugars, salts, amino acids, polymers, buffering agents,
etc.) were evaluated, and promising hits were identified. Then, dif-
ferent excipient combinations and concentrations were optimized.
The selection of excipient ‘‘hits” was based on improvements in
RV3-BB stability upon exposure to freeze–thaw, agitation and
acidic pH conditions using an infectivity-qPCR potency assay as
described elsewhere [23,24]. A series of candidate RV3-BB liquid
formulations were setup on accelerated and long-term stability
studies and monitored using an infectivity-qPCR potency assay,
Fig. 3. Process flow diagram for production of ORV. Solid lines indicate unit-operations; dashed circles indicate materials used.
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intensive and time consuming FFA assay (i.e., the former being a
higher-throughput assay used for formulation development and
the latter used as the official potency assay). Accelerated and
real-time stability data of a series of candidate RV3-BB formula-
tions using the experimental infectivity qPCR assay are described
elsewhere [23,24]. In this work, two-year long-term RV3-BB stabil-
ity data at 2–8 C and 15 C for some of the most promising candi-
date RV3-BB formulations (with varying levels of acid neutralizing
capacity for oral administration without the need for pre-
neutralization of gastric acid) as monitored by the official cell-
based FFA potency assay are shown in Fig. 5. The selected RV3-
BB candidate formulations displayed excellent stability profiles at
2–8 C (with mean slope values of essentially no loss, 0.0 log10
FFU/mL) over 24 months in the absence of an acid neutralizing buf-
fer (F1), and with values ranging 0.0 to 0.5 log10 FFU/mL total loss
over 24 months in the presence of various amounts and types of
acid neutralizing excipients (F2-F5). For example, the 2–8 C
RV3-BB stability profile after 24 months showed a trend of 0.0
log10 FFU/mL loss (with 200 mM adipic acid, F5), 0.1 log10 FFU/
mL loss (with 200 mM sodium succinate, F2), 0.4 log10 FFU/mL loss
(with 400 mM sodium succinate, F3) and 0.5 log10 FFU/mL loss
(with 400 mM sodium acetate, F4). These log loss values are based
on the mean slope values to facilitate comparisons of the various
formulations, however, final shelf-life determination will be based
on the lower 95% CI of the stability data to account for assay and
process variability (see shaded area of Fig. 5). The candidate RV3-
BB liquid formulations were more stable at 2–8 C as compared
to 15 C, the latter temperature allowing for better differentiation
between the candidate formulations (Fig. 5). In addition, these
RV3-BB formulations did not show any viral infectivity losses when
stored frozen at –20 C for 24 months (data not shown). This
promising real-time RV3-BB stability data over 24 months in2052candidate formulations support the implementation of a
refrigerator stable, liquid formulation (see discussion).
2.5. RV-3 BB vaccine: Cost of goods analysis
BioSolve software was used at Batavia Biosciences for COGs
calculations; a Drug Substance Cost of Goods (COGs) model was
developed, and validated in collaboration with BDO’s BioProcess
Technology Group (BDO, Boston, MA, USA) and Duff & Phelps
(D&P, New York, NY, USA) in accordance with methodology devel-
oped with the Bill & Melinda Gates Foundation [33] using Super-
Pro software. Prior to analysis of the calculated manufacturing
costs for the RV3-BB Oral Rotavirus vaccine (ORV), the cost model
was validated using data on UNICEF tender prices for Global Alli-
ance for Vaccines and Immunization (GAVI) LIC countries in the
period 2014–2018 (based on data from WHO [34], assuming a
marginal profit margin for this category of countries. In this period,
ORV (Rotarix by GlaxoSmithKline Biologicals SA, and RotaTeq by
Merck Vaccines) tender prices for GAVI LIC countries were on aver-
age 2.44 USD per dose, and ranged from 1.89 to 3.62 USD per dose
[34]. Based on this information, the target COGs for manufacturing
(i.e., not the anticipated sales price) of our RV3-BB vaccine was set
below this range at 1.17 USD per dose (or 3.50 USD for three
doses).
Details of the developed production process were entered into
the software model (this excluded R&D costs, marketing and distri-
bution costs, and profit margins). For the drug substance COGs
model, the basic unit operations included 64 Cell Factory systems
in one run with the harvests pooled to perform one DSP run. The
COGS analysis showed that USP consumables accounted for 50%
of the materials costs (Fig. 6). Among the USP consumables, both
culture media and Benzonase were identified as major cost dri-
vers. Based on the process developed in this study, a COGs well
Fig. 4. (A & B) HP-SEC analytical method for in-process rotavirus quantification to support process development. Specificity is demonstrated (A). At the retention time of
rotavirus RV3-BB (around 17 min), no interfering peaks are observed for the diafiltration buffer. The purified rotavirus RV3-BB peak is baseline separated with resolution > 2
(B). Fig. 4 (C–F) The peak profile was observed to be shifting from day 1 to day 5 in USP process (day 3 and 5 are shown as examples in figure (C) and (D), which illustrates the
rotavirus replication in USP. After Benzonase treatment the profile shows a baseline separated peak at the retention time around 17 min (comparable to the purified RV3-BB
peak; E and F). As a result, quantification of the rotavirus peak is possible after Benzonase treatment.
A. Hamidi, F. Hoeksema, P. Velthof et al. Vaccine 39 (2021) 2048–2059below the target of $3.50 per course can be delivered at the lower
(6.0 log10 FFU) clinical dose tested in the dose ranging study. If the
middle dose of 6.5 log10 FFU is determined as the clinical dose, the
COGs will be approximately $1.40 above the target of $3.50, but
still substantially below the current average market price of 2.44
USD per dose ($7.32 per three dose course; 2014–2018 UNICEF
tender prices).20533. Discussion
A drug substance manufacturing process for RV3-BB neonatal
rotavirus vaccine bulk production was developed and met the
manufacturing COGs target of less than 3.50 USD per complete vac-
cination course of three doses. The novel virus production process
was designed such that it allows 16 runs on a yearly basis. In virus
Fig. 5. Storage stability profiles of RV3-BB in candidate liquid formulations (F1-F5) over 24 months at 2–8 C and 15⁰C as measured by the FFA cell-based virus potency assay.
The composition of the candidate formulations is shown in Table with each prepared in a phosphate buffer at pH 7.8. Solid lines (slope with units FFU mL1 month1)
represent regression of mean log loss of RV3-BB viral titers at different temperatures and timepoints (squares) vs. –80⁰C control formulation run in the same FFA assay. Mean
log loss values after 24 months based on slope values are also shown. Shaded areas represent 95% confidence interval of stability data.
Fig. 6. Main cost drivers were determined based on the COGs model. Benzonase contributed 10% to the overall COGs. Alternatives for Benzonase were identified based on
the COGs calculations.
A. Hamidi, F. Hoeksema, P. Velthof et al. Vaccine 39 (2021) 2048–2059production, the multiplicity of infection (MOI) was optimized for
10-fold more efficient use of master virus seed-stocks, thus
lowering the COGs. The process consistently delivered a harvest
with the rotavirus titer at 7.3 ± 0.3 log10 FFU/mL and incorporated
use of an animal-origin free, GMP-grade, source of trypsin. For2054virus purification, a robust and scalable 4-step process was
developed providing overall DSP infectious rotavirus recovery of
approximately 30% (including final filtration), or alternatively
>50% when excluding final filtration (requiring aseptic processing).
The relatively high loss of infectious virus observed with final
A. Hamidi, F. Hoeksema, P. Velthof et al. Vaccine 39 (2021) 2048–2059filtration can best be explained by virus clogging the filter pores,
seeing that the virus diameter (77 nm) and the pore size
(200 nm) are in the same order of magnitude. Host-cell DNA impu-
rity level in drug substance and calculated in drug product were
significantly (>99.9%) below WHO and European Pharmacopoeia
human oral rotavirus vaccine regulatory requirements. Finally, a
novel HP-SEC analytical method for virus particle quantification
was developed, which can be used to support future fast-track pro-
cess development, delivering a semi-quantitative high throughput
methodology, without the relatively high assay variation as
observed with biological assays such as FFA.
This rotavirus vaccine process is expected to meet the targeted
low COGs needed for new vaccine manufacturers to implement the
technology, build a sustainable business case, and compete with
currently available rotavirus vaccines. The suitability of a lower
titer vaccine (6.0, 6.5 and 7.0 Log10 FFU) is currently under clinical
investigation in a dose ranging study performed in Malawi by MCRI
(ClinicalTrials.gov Identifier: NCT03483116) and may contribute to
efforts to lower the vaccine cost per dose [35]. In addition, further
process optimization opportunities were identified in USP (use of
fixed-bed bioreactors in combination with trypsin alternatives)
and DSP (use of lower cost alternatives for Benzonase (e.g., DNAr-
ase, which could further reduce overall COGs by 10%), use of asep-
tic processing, or alternative final filtration methods to increase the
overall virus recovery), and may contribute to further reduction of
COGs.
In addition, candidate RV3-BB formulations resulting in a 2–8 C
stable liquid vaccine which do not require pre-neutralization of
gastric acid prior to administration have been developed (as
described in detail elsewhere [23,24]). In this work, 2-year, real-
time (2–8 C) and accelerated (15 C) stability data with some of
the key candidate RV3-BB liquid formulations as measured by
the FFA viral infectivity assay are presented. The development of
a stable liquid formulation of a live, attenuated viral vaccine can
be challenging due to the inherent instability of live viruses and
variability observed in viral infectivity assays [36]. Moreover, addi-
tional factors including the ‘‘stability window” between the viral
titer required at release (highest dose that is safe) and expiry (low-
est dose that is efficacious) for a specific vaccine candidate must be
considered as part of process development and clinical trials [37].
Because of the observed promising RV3-BB real time storage stabil-
ity profiles demonstrated in this work (Fig. 5), a lower virus con-
centration in the vial can potentially now be targeted (depending
on final selection of target dose based on ongoing Malawi clinical
trials; see above), which in turn could contribute to lowering the
overall COGs. Although a stable liquid RV3-BB liquid formulation
is expected based on this work, final determination of shelf-life
and VVM designation will require future determination of (1) stor-
age stability profiles of RV3-BB bulks in the selected final formula-
tion produced in the final manufacturing facility and filled into the
commercial primary container, (2) determination of lower 95% CI
of the stability data assayed by the final version of the FFA cell
based potency assay, and (3) the clinically required RV3-BB virus
dose at release and expiry. In addition, accelerated stability data
using the FFA assay will need to be obtained with RV3-BB virus
from the final manufacturing conditions as part of future work.
These data will be used to determine the Vaccine Vial Monitor
(VVM) designation of the RV3-BB vaccine candidate in the final for-
mulation [38]. Currently, initial short-term accelerated stability
data are being collected for some of these candidate RV3-BB liquid
formulations using an experimental viral infectivity qPCR assay,
and assessments of the ability to model accelerated stability data
(15, 25 and 37 C) to predict long-term, real-time stability data
(2–8 C) are ongoing and will be described separately [25].
We thus describe a robust production protocol for a 2–8 C
stable liquid formulation of the RV3-BB virus vaccine candidate.2055Historically, when using FRhL-2 cells in rotavirus vaccine
manufacturing, reported virus titers were approximately 105 –
108 PFU/mL, and purification was not required [39]. Thus the vac-
cine dose of 105 PFU/re-assortant/dose could simply be obtained
by dilution [39]. Currently, the licensed rotavirus vaccines (Rota-
Teq, Rotarix, ROTAVAC and ROTASIIL) are Vero cell-derived
[40–42]. However, no peer reviewed details have been published
regarding the applied vaccine manufacturing processes, cell and
virus culture methods, purification, and filtration methods or the
observed in-process yields. We therefore embarked upon our stud-
ies with an openness to consider a wide range of possible options
for the process being developed.
In the upstream process developed for RV3-BB, several
advantages were offered by use of the iCELLis bioreactor for
RV3-BB production. These included a small manufacturing foot-
print, large bed size of 500 m2 for scale-up, relative ease of use,
and as a result, the potential for a low COGs if acceptable yields
could be obtained. Yield comparison between iCELLis nano
(6.0 ± 0.2 log10 FFU/mL) and Cell Factory systems (7.3 ± 0.3 log10
FFU/mL), however, showed that titers obtained in the Cell Factory
systems were in the expected and required range, when using a
non-animal trypsin source, and thus this cell culture system was
selected to continue for further process development.
To increase virus production yields through process
optimization, three key factors were considered: i) cell concentra-
tion and metabolic/physiological status of the cells at time of infec-
tion, ii) ratio of infectious particles to viable cells at the time of
infection, and iii) residence time of virus particles within the biore-
actor and time point of harvest [43]. Regarding the residence time,
once maximum titers have been achieved, virus infectivity and the
total number of virus particles can decrease again [39]. Based on
this knowledge, optimization strategies were introduced and
included shortening the process time due to an adapted Vero cell
preculture schedule (for increased yearly production capacity)
and screening of process parameters as cell density at infection
(CDAI), MOI and cell growth and infection media. Ultimately, the
process was fixed using a MOI 10x lower compared to the initial
process to make efficient use of master virus seed (MVS) stocks.
When using diploid host cells such as FRhL-2 cells, moderate to
no purification is required for rotavirus vaccine due to the oral deliv-
ery and the cell substrate used [39,44]. With the use of other cell
lines such as Vero, for example, alternative rotavirus purification
approaches using chromatographic methods have been proposed
in the literature [45,46] aswell as alternativemembranechromatog-
raphy purification methods for rotavirus-like particles [47,48]. In
follow-up studies, these alternative methods could be considered
in the DSP to achieve comparable impurity removal and improved
recovery. Alternatively, omitting the final sterile filtration step in
the process developed here for RV3-BB will deliver a significantly
increased DSP recovery and can be used in combination with an
aseptic process for the manufacturing of this oral vaccine.
The Cell Factory system was chosen for the current process
development, and for the COGs scenario, a comparable overall
facility capacity between 34 and 40 M doses per annum was
assumed. The overall drug product COGs range estimation for both
USP system alternatives (i.e. iCELLis fixed-bed bioreactor versus
Cell Factory systems) appeared comparable. This overall DP COGs
range was independently confirmed using alternative software
(SuperPro Designer). Main cost drivers were culture media and
Benzonase for both USP options, followed by trypsin when using
the iCELLis system; the cost of Benzonase overtaken by labor for
the Cell Factory-based process. Using the developed COG’s model,
scenario analyses were performed by an external independent
party (BPTC/D&P), and included one, five, and ten dose vial fills
(Fig. 7). If, for example, the cost objective was fixed at the indicated
future large-scale lower COGs target level of 3.50 USD per course
Fig. 7. (A-C) USP Yield (Fig. 7A), DSP recovery(Fig. 7B) and vial fill dose (Fig. 7C) scenario analyses. Base cases indicate the applicable base-case process (harvest yield 7.3 log10
FFU/mL and DSP recovery of 30%) and formulated dose (6.9 log10 FFU in Phase I clinical trial). Dashed line indicates opportunities to reach the targeted cost (USD 3.50) per
three dose course.
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doses per vial), this goal can be achieved in only a limited number
of scenarios: (i) an increased USP virus titer, and/or (ii) an
increased overall DSP recovery level, and/or (iii) a decreased clini-
cal dose level.
While scenario i) was feasible using the currently developed
process, scenarios ii) and iii) could be explored further to achieve
the lower cost objective. In DSP, selection of alternative final filtra-
tionmethods, or the application of aseptic processing, may increase
overall DSP recovery significantly (>50%), resulting in achievement
of an even lower cost per course objective. Alternatively, the cost
target may be further reduced by choosing a lower dose.
Recently, the direct vaccine cost (excluding waste) for GAVI-
supported rotavirus vaccines in the period 2019–2021 was
reported to range lower, between 0.85 and 2.29 USD per dose
[10]. One dose of these vaccines contain 6.0 log10 CCID50 (used
in a 2-dose regimen) per dose, 5.0 log10 FFU (used in a 3-dose reg-
imen) per dose, and 5.6 log10 FFU for five strains each per dose
(used in a 3-dose regimen), for Rotarix [49], ROTAVAC [50],
and ROTASIIL [42], respectively. Feasibility of this COGs range is
also illustrated by the recently introduced and WHO prequalified
rotavirus vaccine (ROTAVAC) by Bharat Biotech. ROTAVAC was
initially reported to be offered at 0.95 USD/dose to the Government
of India [51], and currently priced (for the period 2017–2021) at
0.85 USD/dose for UNICEF [52]. To enable this even lower direct
RV3-BB vaccine cost, the main cost drivers and several opportuni-
ties for process optimization were identified above. From the COGs
data, it was observed that with high yearly facility capacity (>40 M
doses/year), use of a fixed-bed bioreactor could lower the cost per
dose when using a certain trypsin source.
The lowest and middle dose both resulted in the COGs still
substantially below the current average market price of 2.44 USD
per dose ($7.32 per three dose course; 2014–2018 UNICEF tender
prices). The COGs of the lowest clinical dose were well below the
target of $3.50 per course. For the middle dose the COGs will
be approximately $1.40 above the target of $3.50, but still substan-
tially below the current average UNICEF tender price. In addition,
we have identified several areas by which the process COGs can
be further reduced, for example by replacing the Benzonase with
a lower cost alternative such as DNArase, which could reduce COGs
by 10%. Further, the above mentioned COGs is for a process includ-
ing a final sterile filtration step, a process step that can be omitted
when producing an Oral vaccine under aseptic conditions.4. Materials & methods
Cell line: WHO Vero 10–87 derived working cell banks were
used. Initially, the Batavia Vero working cell bank was used for
small scale screening experiments. During drug substance manu-
facturing process development, the BioFarma Vero working cell
bank was used for process confirmation and local implementation.
Virus: The RV3 strain was isolated at the Royal Children’s
Hospital (Melbourne, Australia), and currently further developed
as the RV3-BB vaccine at Murdoch Children’s Research Institute
[6,15,16]. Clinical trial lots for phase I, IIa, IIb and dose ranging
studies conducted by MCRI were manufactured under GMP by
Meridian Life Sciences, Memphis (USA) at a titer of 8.6  106 FU/
ml. RV3-BB vaccine was provided to BioFarma to manufacture
the RV3-BB under license from MCRI. A vial of the BioFarma
RV3-BB working virus bank was passaged four times on Vero cells
to generate a research virus bank used for the experiments.
Culture media and chemicals: Commercial cell and virus culture
media, Bovine Serum from certified TSE free sources was used in
USP, trypsin, and animal-component-free trypsin alternatives were
used. Benzonase was obtained from Merck Chemicals.2057Cell culture systems: T-flasks (Greiner), iCELLis nano
(fixed-bed bioreactor; PALL), and scale-X Hydro (fixed-bed bioreac-
tor; Univercells) were used in the cell culture system selection
stage. In the drug substance manufacturing process development
stage, Cell Factory systems (Easy Fill CF10; Thermo Fisher
Scientific) were used.
Analytical methods: ELISA methods were applied for Vero
host-cell protein (Cygnus Technologies, catalog nr. F500), residual
BSA (Cygnus Technologies, catalog nr. F030), and residual Ben-
zonase (Merck, catalog nr. 1.01681.0001). For Vero host-cell
DNA, a QPCR method was applied (Thermo Fisher, catalog nr.
4460367). The Focus Forming Assay (FFA) was developed as a con-
tent/potency assay according to ICH Q2 guidelines [32]. In the FFA,
MA104 cells are infected with rotavirus and the read-out is by
fluorescence microscopy to count and quantify the number of
fluorescent cells. Results of the FFA are expressed as focus forming
units per milliliter, or FFU/mL.
Cost modelling (software and assumptions made): Based on the
process development at Batavia, and using industrial manufactur-
ing costs (including depreciation time and rate, exchange rates,
facility availability, overhead, maintenance, implementation of
single-use bioreactor and buffer preparation systems, waste man-
agement, working hours, personnel, materials, packaging, licens-
ing, and distribution) input from BioFarma, a drug substance
COGs model was developed, and validated in collaboration with
BDO’s BioProcess Technology Group (BDO, Boston, MA, USA) and
Duff & Phelps (D&P, New York, NY, USA). The initial drug substance
COGs model was developed using BioSolve Process software (v7)
(Biopharm Services Ltd., Chesham, UK), and the model was vali-
dated independently using SuperPro Designer (v9) (Intelligen
Inc, Scotch Plains, NJ, USA) by BDO’s BioProcess Technology Group.
In addition, a fill and finish model were developed in SuperPro
Designer, to also include drug product cost estimations.
The cost models were defined by a detailed process description
including USP and DSP unit operations, process scale (equipment
sizing), product titers and resources allocation. A cost database,
which is built with data consisting of benchmarking information
including equipment and materials, is coupled to calculate costs
for the process. Together with the required utilities, the manufac-
turing COGs can be determined. The complete ORV manufacturing
process (3) was described to calculate the manufacturing costs per
dose for two process options, based on Cell FactoryTM or iCELLis
use in USP, to assess the cost drivers, and identify targets for the
reduction of the COGs.
Formulation and stability: The development and preparation of
candidate RV3-BB formulations, along with the design of the accel-
erated and real-time stability program, is described in detail else-
where [23]. Briefly, selected candidate formulations were
prepared, mixed with RV3-BB virus bulks, filled into stoppered
glass vials. Samples were removed at indicated times and temper-
atures, stored at 80 C and subsequently assayed for RV3 infectiv-
ity values by FFA assay. At each stability time point, the samples
stored at 2–8 C and 15 C were assayed along with the same can-
didate formulation stored frozen at 80 C. Stability values are
expressed as log loss vs the 80 C control formulation. This
approach improves stability estimations by lowering assay
variability as described in detail elsewhere [25].Declaration of Competing Interest
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